CUE — Cue Biopharma Income Statement
0.000.00%
Last trade - 00:00- $59.16m
- $41.03m
- $9.29m
Annual income statement for Cue Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.15 | 14.9 | 1.25 | 5.49 | 9.29 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 48.2 | 58.7 | 54.5 | 57.6 | 50.8 |
| Operating Profit | -45 | -43.7 | -53.2 | -52.1 | -41.5 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -44.6 | -43.7 | -53 | -50.7 | -40.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -44.8 | -44.2 | -53 | -50.7 | -40.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -44.8 | -44.2 | -53 | -50.7 | -40.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -44.8 | -44.2 | -53 | -50.7 | -40.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.56 | -1.41 | -1.49 | -1.11 | -0.724 |